UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name on exchange on which registered Common Stock, $0.001 par value per share HROW The Nasdaq Stock Market LLC 8.625% Senior Notes due 2026 HROWL The Nasdaq Stock Market LLC 11.875% Senior Notes due 2027 HROWM The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REP ...

EXHIBIT 99.1 Harrow Announces Second Quarter 2024 Financial Results Second Quarter 2024 and Recent Selected Highlights: ● Record revenues of $48.9 million ● GAAP net loss of $(6.5) million ● Adjusted EBITDA of $8.8 million ● Cash and cash equivalents of $71.0 million as of June 30, 2024 ● IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 ● IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina pra ...

So, the price trend in HROW may not reverse anytime soon. In addition to HROW, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria. This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market. However, keep ...

Harrow (HROW) shares soared 12.9% in the last trading session to close at $19.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.5% gain over the past four weeks. This pharmaceutical and drug compounding company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of -1150%. Revenues are expected to be $42.78 million, up 27.8% from the year-ago quarter. For Harr ...

| 17 | Investor Presentation | May 2024 • Steroids, NSAIDs, and Anti-inflammatories • an OTC preservative-free lubricant • an Antihistamine, and Antibiotics cyclosporine ophtha emulsion 0.1% "We know steroids effectively treat inflammation in DED. FLAREX is further differentiated from other steroids by increasing MUC1, MUC4, MUC16, and MUC19 gene expression in the conjunctival and corneal epithelial cells. Mucin is a critical component of DED in providing protection and binding the tear film to the ocular s ...

Harrow, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call Transcript May 14, 2024 8:00 AM ET Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference Call Participants Operator Good day, everyone, and welcome to the Harrow, Inc. First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recor ...

ia_64/iStock via Getty Images Shares of ophthalmology-focused specialty pharmaceutical concern Harrow, Inc. (NASDAQ:HROW) are down some 45% since their highs in the spring of 2023. However, they seem likely to rebound as the market starts to look at the potential for Iheezo. Its launch and that of dry eye therapy Vevye suggest that the company's FY24 net revenue outlook of $180 million plus might be very conservative. In addition, the recent insider and beneficial owner buying also merited a deeper dive. Se ...

What was the first part, Mayank, I missed it. Mark L. Baum And so in the face of those sorts of opportunities in front of us, we thought it was prudent to confirm with CMS that, in fact, our J-code, which is a product-specific permanent J-code, would, in fact, be separately reimbursable in the physician's office setting. And so as we promised in the last letter to stockholders, we requested a meeting with CMS. We had that meeting on January 9th, and we have been waiting patiently to hear from them. Mayank M ...

"VEVYE represents a breakthrough in dry eye treatment. Patients with sensitive eyes, often susceptible to side effects from prescription eyedrops, finally have a solution. VEVYE is the first topical immunomodulator that hasn't had any side effects of stinging, while also having the highest concentration of cyclosporine on the market. Unsurprisingly, the feedback from patients has been tremendous." "VEVYE's performance has been outstanding in terms of accessibility, especially for a new entrant to the pharma ...

Exhibit 99.2 Letter to Stockholders March 19, 2024 Dear Harrow Stockholders: Please review our new corporate presentation to supplement this Letter to Stockholders. Four Years of Accomplishment The legendary investor Warren Buffett once said, "Some people like to get rich quick, but I like to get rich slow." Buffett often quoted his friend and former Goldman Sachs senior executive, Gustave "Gus" Levy, who said, "Short-term greed leads to bad long-term results." And finally, my friend Don Miloni – who helped ...